Back HCV Populations

Coverage of 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016)

HIVandHepatitis.com coverage of the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016), September 7-9 in Oslo, Norway.

Highlights include hepatitis C treatment for people who inject drugs and people in prison, extra-hepatic manifestations of hepatitis C, and development of an HCV vaccine.

INHSU 2016 coverage listing

INHSU 2016 website

9/3016

alt

Interferon-Free Hepatitis C Treatment Safe and Effective for People Who Inject Drugs

Chronic hepatitis C patients on opioid substitution therapy, including those who continue to use illicit drugs, maintained good adherence and had high sustained response rates when treated with sofosbuvir/ledipasvir (Harvoni) or sofosbuvir/velpatasvir (Epclusa), according to a pair of ad-hoc analyses published in the August online edition of Clinical Infectious Diseases.

alt

Read more:

EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains

People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona. However, the same study saw several cases of hepatitis C virus (HCV) reinfection after a cure, suggesting a greater emphasis on prevention may be warranted.

alt

Read more: